Review
doi: 10.1254/fpj.126.353.
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy]
[Article in
Japanese]
Affiliations
- PMID: 16394581
- DOI: 10.1254/fpj.126.353
Item in Clipboard
Review
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy]
[Article in
Japanese]
Nihon Yakurigaku Zasshi.
2005 Nov.
No abstract available
Similar articles
-
[Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].Nihon Yakurigaku Zasshi. 2009 Sep;134(3):149-57. doi: 10.1254/fpj.134.149. Nihon Yakurigaku Zasshi. 2009. PMID: 19749488 Review. Japanese. No abstract available.
-
Zoledronic acid: a new parenteral bisphosphonate.Clin Ther. 2003 Nov;25(11):2669-708. doi: 10.1016/s0149-2918(03)80327-2. Clin Ther. 2003. PMID: 14693298 Review.
-
Hypercalcemia of malignancy remains a clinically relevant problem.Cancer J. 2006 Jan-Feb;12(1):21-3. doi: 10.1097/00130404-200601000-00005. Cancer J. 2006. PMID: 16613658 No abstract available.
-
Mismanagement of malignant hypercalcaemia.Clin Med (Lond). 2013 Feb;13(1):118. doi: 10.7861/clinmedicine.13-1-118. Clin Med (Lond). 2013. PMID: 23472518 Free PMC article. No abstract available.
-
[Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].Clin Calcium. 2007 Jan;17(1):24-8. Clin Calcium. 2007. PMID: 17211090 Review. Japanese.
